Sano Genetics raises £8m to connect rare disease patients with medicine providers

sano genetics founders

Sano Genetics, a startup that has developed a platform to connect patients that have rare, chronic diseases with personalised medicine providers, has raised $11m (£8.4m) in a Series A funding round.

Cambridge-based Sano Genetics will use the capital injection to develop its platform to meet demand for over 50 diseases and over 6 countries by mid 2023. Furthermore, it will use the funding to expand its teams in the US and Europe.

Sano Genetics’ software allows patients with rare and chronic conditions, such as Parkinson’s, to contribute to precision medicine research at no cost and from home.

The company then charges a subscription to its pharma, biotech and population health clients.

“It still takes 10 to 15 years for new drugs to reach patients, and many will never make it out of R&D because costs are prohibitive,” said Dr Patrick Short, CEO and co-founder of Sano Genetics. “This funding takes us closer to our mission to build the platform that we, and many others – patients and researchers – wish was available a decade ago.

“One that will make research much faster, more cost-effective, and a vastly better experience for patients.”

MMC Ventures led the funding round, with further investment coming from Episode 1 and Seedcamp. Sano Genetics also attracted backing from angel investors including Indeed co-founder Paul Forster, former VP of innovation at PatientsLikeMe Paul Wicks and former Ancestry.com CEO Margo Georgiadis.

Sano Genetics has previously raised £500,000 in a seed funding round in June 2019 and £2.5m in a secondary seed round in January 2021. Its total investment to date is £11.3m.

The company was founded in 2017 by University of Cambridge genomics students Charlotte Guzzo (COO), Patrick Short (CEO) and William Jones (CTO).

Lead investor MMC Ventures has previously funded Gousto, Current Health and Signal AI.

“There is an urgent need to solve the largest problems in clinical trials: patient recruitment and engagement. This is where Sano’s innovative software platform, which allows them to interact directly with patients, biotech and broader healthcare communities, can be transformational for the future of personalised medicine,” said Charlotte Barttelot, investor at MMC Ventures.